Navigate all the latest information in myeloproliferative neoplasms, arranged by experts and health care professionals. Listed below are recently added expert opinions.
What do we know about the outcome of concomitant MPN and COVID-19?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee members Laura Michaelis, Medical...
How would you manage a young man with polycythemia vera and fatigue?
Interview with Gabriela Hobbs during the 2020 Annual Meeting of the SOHO. We asked the question: How would you manage a young man...
How can we predict and reduce the risk of thrombosis in a patient with PV?
Interview with Gabriela Hobbs during the 2020 Annual Meeting of the SOHO about reducing the risk of thrombosis in a patients...
Myeloproliferative neoplasms, thrombosis, and COVID-19
Myeloproliferative neoplasms (MPN) are associated with a high prevalence of thrombosis at diagnosis: 28.6% in polycythemia vera (PV), 20.7% in...
The practical use of myelofibrosis genomics in a clinical setting
Myelofibrosis (MF), a subtype of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), is characterized by Janus...
The microbiome and its effects on the immune system
The MPN Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San Francisco, US, and Diwakar Davar, University...
How would you manage a young woman with thrombocytosis?
Interview with Prithviraj Bose during SOHO 2020 providing an outline on how to manage a specific patient case.
How should genomic assessment in MF be performed?
Interview with Raajit K. Rampal during SOHO 2020 about how genomic assessment should be performed in patients with myelofibrosis.
Alessandro M. Vannucchi
Haifa Kathrin Al-Ali
Jacqueline S. Garcia
Raajit K. Rampal
Ruben A. Mesa